###begin article-title 0
###xml 155 156 155 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn1">*</xref>
Biochemical, Functional, and Pharmacological Characterization of AT-56, an Orally Active and Selective Inhibitor of Lipocalin-type Prostaglandin D Synthase*
###end article-title 0
###begin p 1
Both of these authors contributed equally to this work.
###end p 1
###begin p 2
Present address: Nippon Bio-test Laboratories Inc., 1-15-3 Higashitokura, Kokubunji, Tokyo 185-0002, Japan.
###end p 2
###begin p 3
###xml 96 112 96 112 <email xmlns:xlink="http://www.w3.org/1999/xlink">uradey@obi.or.jp</email>
 To whom correspondence should be addressed. Tel.: 81-6-6872-4851; Fax: 81-6-6872-2841; E-mail: uradey@obi.or.jp.
###end p 3
###begin p 4
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice
###end p 4
###begin p 5
 applies to Author Choice Articles
###end p 5
###begin p 6
###xml 30 31 30 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 32 33 32 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 63 64 63 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 276 277 275 276 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 511 512 510 511 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 515 516 514 515 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 514 516 513 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 524 525 522 523 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 535 536 533 534 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 534 536 532 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>i</sub></italic>
###xml 551 552 548 549 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 591 594 588 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 814 815 811 812 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 881 883 878 880 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 899 900 895 896 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 919 921 915 917 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 941 942 936 937 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 984 985 979 980 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 993 999 988 990 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2&#945;</sub>
###xml 1028 1029 1019 1020 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1151 1152 1142 1143 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1301 1302 1292 1293 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1310 1316 1301 1303 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2&#945;</sub>
###xml 224 229 <span type="species:ncbi:9606">human</span>
###xml 234 239 <span type="species:ncbi:10090">mouse</span>
###xml 837 842 <span type="species:ncbi:9606">human</span>
###xml 1062 1067 <span type="species:ncbi:9606">human</span>
###xml 1204 1208 <span type="species:ncbi:10090">mice</span>
###xml 1471 1476 <span type="species:ncbi:9606">human</span>
###xml 1484 1499 <span type="species:ncbi:10090">transgenic mice</span>
We report here that 4-dibenzo[a,d]cyclohepten-5-ylidene-1-[4-(2H-tetrazol-5-yl)-butyl]-piperidine (AT-56) is an orally active and selective inhibitor of lipocalin-type prostaglandin (PG) D synthase (L-PGDS). AT-56 inhibited human and mouse L-PGDSs in a concentration (3-250 mum)-dependent manner but did not affect the activities of hematopoietic PGD synthase (H-PGDS), cyclooxygenase-1 and -2, and microsomal PGE synthase-1. AT-56 inhibited the L-PGDS activity in a competitive manner against the substrate PGH2 (Km = 14 mum) with a Ki value of 75 mum but did not inhibit the binding of 13-cis-retinoic acid, a nonsubstrate lipophilic ligand, to L-PGDS. NMR titration analysis revealed that AT-56 occupied the catalytic pocket, but not the retinoid-binding pocket, of L-PGDS. AT-56 inhibited the production of PGD2 by L-PGDS-expressing human TE-671 cells after stimulation with Ca2+ ionophore (5 mum A23187) with an IC50 value of about 3 mum without affecting their production of PGE2 and PGF2alpha but had no effect on the PGD2 production by H-PGDS-expressing human megakaryocytes. Orally administered AT-56 (<30 mg/kg body weight) decreased the PGD2 production to 40% in the brain of H-PGDS-deficient mice after a stab wound injury in a dose-dependent manner without affecting the production of PGE2 and PGF2alpha and also suppressed the accumulation of eosinophils and monocytes in the bronco-alveolar lavage fluid from the antigen-induced lung inflammation model of human L-PGDS-transgenic mice.
###end p 6
###begin p 7
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice-Final version full access.
###end p 7
###begin p 8
###xml 52 91 52 91 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Japan Foundation for Applied Enzymology</grant-sponsor>
###xml 121 140 121 140 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Scientific Research</grant-sponsor>
###xml 174 184 174 184 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Osaka City</grant-sponsor>
###xml 327 340 327 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">advertisement</italic>
This work was supported in part by a grant from the Japan Foundation for Applied Enzymology (to K. A.), Grant-in Aid for Scientific Research of MEXT 19590094 (to K. A.), and Osaka City. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 4 5 4 5 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn4">4</xref>
###xml 45 46 45 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 48 49 48 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 79 80 79 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref3">3</xref>
###xml 86 87 86 87 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 132 136 132 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e.</italic>
###xml 139 140 139 140 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref4">4</xref>
###xml 151 152 151 152 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 175 176 175 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 184 185 184 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 203 204 203 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 206 207 206 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 219 220 219 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref7">7</xref>
###xml 228 229 228 229 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 341 342 341 342 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 354 355 354 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 430 431 430 431 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 443 444 443 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 478 479 478 479 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 580 581 580 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
PGD24 is a lipid mediator involved in sleep (1, 2) and inflammatory responses (3). PGD2 activates two different types of receptors (i.e. DP1 (4) and DP2 (also known as CRTH2 (5))). PGD2 regulates sleep (2, 6) and pain (7) via DP1 receptors in the central nervous system. This prostanoid also causes contraction of airway smooth muscle via DP1 receptors (8) and mediates chemotaxis of eosinophils and basophils into the lung via DP2 receptors (9) in the periphery. Therefore, PGD2 coordinately regulates allergic reactions, especially airway inflammation, via these two receptors (9).
###end p 9
###begin p 10
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 112 113 112 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 192 194 192 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 319 320 319 320 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 421 422 421 422 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 451 452 451 452 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 552 554 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 555 557 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 592 594 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
PGD2 is formed by the following sequence of enzyme reactions after cell activation: 1) cytosolic phospholipase A2 is translocated to the endoplasmic reticulum and perinuclear membranes in a Ca2+-dependent manner, where it cleaves arachidonic acid from the membrane phospholipids; 2) arachidonic acid is converted to PGH2, a common precursor of various prostanoids, by the membrane-bound cyclooxygenases (COXs); and 3) PGH2 is further isomerized to PGD2 by PGD synthase (PGDS). There are two distinct types of PGDS, namely lipocalin-type PGDS (L-PGDS) (10-13) and hematopoietic PGDS (H-PGDS) (14-16).
###end p 10
###begin p 11
###xml 43 44 43 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 84 86 84 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref18">18</xref>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 254 255 254 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 344 346 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref28">28</xref>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref29">29</xref>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref30">30</xref>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
###xml 499 501 496 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref31">31</xref>
###xml 488 493 <span type="species:ncbi:9606">human</span>
L-PGDS contributes to the production of PGD2 in the central nervous system (10, 17, 18), ocular tissues (19), cardiovascular systems (20), and male genital organs (21) of various mammals and is involved in the regulation of non-rapid eye movement sleep (2, 22), sex determination (23), protection of atherosclerosis (24, 25), and adipogenesis (26). L-PGDS is secreted into the cerebrospinal fluid (CSF) (27, 28), seminal plasma (29, 30), and plasma (20) as beta-trace, a major protein in human CSF (31).
###end p 11
###begin p 12
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref32">32</xref>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref33">33</xref>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref35">35</xref>
###xml 356 358 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref36">36</xref>
###xml 385 386 382 383 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 384 386 381 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>d</sub></italic>
###xml 397 398 394 395 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 651 652 641 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 667 669 657 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref37">37</xref>
###xml 858 860 848 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref38">38</xref>
###xml 862 864 852 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref39">39</xref>
L-PGDS is the only enzyme among the members of the lipocalin gene family (11), which is composed of various secretory proteins involved in binding and transporting small lipophilic substances, such as retinoids and thyroids (32). L-PGDS also binds retinoic acid, retinal (33), biliverdin (34), bilirubin (34), gangliosides (35), and amyloid beta peptides (36) with high affinities of Kd = 20-200 nm, indicating that L-PGDS may act as a transporter protein of these lipophilic compounds and as an endogenous chaperon to prevent amyloid beta aggregation. On the other hand, H-PGDS is the first known vertebrate homolog of the sigma class of glutathione S-transferases (37). Because both of these enzymes have evolved from different origins to acquire the same catalytic function, these two enzymes are considered to be a new example of functional convergence (38, 39).
###end p 12
###begin p 13
###xml 35 37 35 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4+</sup>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref40">40</xref>
###xml 285 286 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref41">41</xref>
###xml 408 409 408 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 453 459 453 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref42">42</xref>
###xml 729 732 729 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a,d</italic>
###xml 762 763 762 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 805 811 805 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 848 850 848 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref43">43</xref>
###xml 927 934 927 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 237 241 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 279 283 <span type="species:ncbi:10090">mice</span>
Inorganic quadrivalent selenium (Se4+) compounds are known to be noncompetitive and reversible inhibitors of L-PGDS (40) and to inhibit the sleep of animals in a time- and dose-dependent manner after infusion into the third ventricle of rats or an intraperitoneal injection into mice (2, 41). However, no organic inhibitor of L-PGDS has been reported until now. We recently found that 4-benzhydryloxy-1-(3-(1H-tetrazol-5-yl)-propyl)-piperidine (HQL-79; Fig. 1) is an orally active and selective inhibitor of H-PGDS (42). Because L-PGDS catalyzes the same reaction as H-PGDS, we suspected that some derivative(s) of HQL-79 might have an inhibition activity toward L-PGDS. Among various tetrazol compounds, we found that 4-dibenzo[a,d]cyclohepten-5-ylidene-1-[4-(2H-tetrazol-5-yl)-butyl]-piperidine (AT-56; Fig. 1) is a specific inhibitor of L-PGDS (43), having a higher potency and biological availability than seleno-compounds in vivo.
###end p 13
###begin p 14
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 1.</label>
###xml 9 49 9 49 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="15">Chemical structures of HQL-79 and AT-56.</p>
###xml 9 49 9 49 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="15">Chemical structures of HQL-79 and AT-56.</p></caption>
###xml 49 49 49 49 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0140969560001"/>
###xml 0 49 0 49 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig1"><label>FIGURE 1.</label><caption><p textid="15">Chemical structures of HQL-79 and AT-56.</p></caption><graphic xlink:href="zbc0140969560001"/></fig>
FIGURE 1.Chemical structures of HQL-79 and AT-56.
###end p 14
###begin p 15
Chemical structures of HQL-79 and AT-56.
###end p 15
###begin p 16
###xml 109 110 109 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 271 272 271 272 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 337 341 <span type="species:ncbi:10090">mice</span>
###xml 347 352 <span type="species:ncbi:9606">human</span>
###xml 391 395 <span type="species:ncbi:10090">mice</span>
In the present study, we characterized AT-56 and found it to be a competitive inhibitor of L-PGDS against PGH2 by kinetic analysis and also used NMR analysis to determine the binding mode of AT-56 to L-PGDS. In addition we found that AT-56 inhibited the production of PGD2 by L-PGDS-expressing cultured cells, H-PGDS gene knock-out (KO) mice, and human L-PGDS overexpressing transgenic (TG) mice.
###end p 16
###begin title 17
EXPERIMENTAL PROCEDURES
###end title 17
###begin p 18
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chemicals</italic>
###xml 120 128 120 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 312 313 311 312 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 353 354 351 352 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 196 200 <span type="species:ncbi:10090">mice</span>
Chemicals-AT-56 was a generous gift from TAIHO Pharmaceutical Company (Saitama, Japan). AT-56 was dissolved in DMSO for in vitro experiments and in 0.5% methylcellulose for oral administration to mice, due to its high lipophilicity. In aqueous solution, the maximum solubility of AT-56 was determined to be 90 mum in saline containing 1% DMSO and 260 mum in 10% DMSO, as determined by UV absorption at 287 nm. Other reagents were purchased from Sigma or Wako (Osaka, Japan), unless otherwise specified.
###end p 18
###begin p 19
###xml 0 34 0 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Purification of Human CSF L-PGDS (</italic>
###xml 38 74 35 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-Trace) and Recombinant Mouse L-PGDS</italic>
###xml 215 217 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref36">36</xref>
###xml 16 21 <span type="species:ncbi:9606">Human</span>
###xml 62 67 <span type="species:ncbi:10090">Mouse</span>
###xml 75 80 <span type="species:ncbi:9606">Human</span>
###xml 123 128 <span type="species:ncbi:9606">human</span>
Purification of Human CSF L-PGDS (beta-Trace) and Recombinant Mouse L-PGDS-Human CSF L-PGDS (beta-trace) was purified from human CSF, which was donated by Dr. M. Mase (Nagoya City University Hospital), as reported (36).
###end p 19
###begin p 20
###xml 378 394 369 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 930 932 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref44">44</xref>
###xml 1060 1061 1044 1045 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 25 30 <span type="species:ncbi:10090">mouse</span>
###xml 378 394 <span type="species:ncbi:562">Escherichia coli</span>
The full-length cDNA for mouse L-PGDS, which is composed of 189 amino acid residues (GenBanktrade mark accession number X89222), was ligated into the BamHI-EcoRI site of the expression vector pGEX-2T plasmid (GE Healthcare). The N-terminal 22-amino acid residues of the signal peptide were deleted, and the C89A/C186A- and W54A-substituted recombinant enzymes were expressed in Escherichia coli DH5alpha (TOYOBO, Osaka, Japan). Site-directed mutagenesis was performed by using a QuikChange(R) site-directed mutagenesis kit (Stratagene, La Jolla, CA). The recombinant enzymes retained PGDS activity comparable with that of the wild-type enzyme and were stable for long term use. The mutated L-PGDS was expressed as a GSH transferase fusion protein, purified by column chromatography with GSH-Sepharose 4B (GE Healthcare), and eluted from the column by incubation with thrombin (100 units/100 mul of resin), as reported previously (44). The recombinant protein was further purified to apparent homogeneity by gel filtration chromatography with Superdex 75 in 5 mm Tris/HCl (pH 8.0).
###end p 20
###begin p 21
###xml 0 29 0 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fluorescence Quenching Assays</italic>
###xml 33 36 33 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 97 98 97 98 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 144 147 144 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 241 242 239 240 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 518 520 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref44">44</xref>
Fluorescence Quenching Assays-13-cis-Retinoic acid and AT-56 were dissolved in DMSO to give a 2 mm stock solution. Various concentrations of 13-cis-retinoic acid and AT-56 in 10 mul of DMSO were added to the L-PGDS solution in 990 mul of 5 mm Tris/HCl (pH 8.0). After incubation at room temperature for 60 min, the intrinsic tryptophan fluorescence was detected with an FP-750 spectrofluorometer (JASCO, Tokyo, Japan) at an excitation wavelength at 282 nm and an emission wavelength at 338 nm, as reported previously (44).
###end p 21
###begin p 22
###xml 0 22 0 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Enzyme Activity Assays</italic>
###xml 52 54 52 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref45">45</xref>
###xml 65 67 65 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref46">46</xref>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref47">47</xref>
###xml 138 139 137 138 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 143 145 142 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink">14</sup>
###xml 150 151 149 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 175 176 174 175 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 217 218 216 217 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 323 325 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref48">48</xref>
###xml 337 338 335 336 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 342 344 340 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">14</sup>
###xml 405 406 403 404 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 440 441 437 438 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 454 457 451 454 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m l</sc>
###xml 582 584 579 581 <sup xmlns:xlink="http://www.w3.org/1999/xlink">14</sup>
###xml 607 609 604 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink">14</sup>
Enzyme Activity Assays-Enzyme activities of L-PGDS (45), H-PGDS (46), and microsomal PGE synthase (m-PGES-1 (47)) were measured with 10 mum [1-14C]PGH2 as a substrate in 100 mm Tris-HCl, pH 8.0, in the presence of 1 mm GSH, 0.1 mg/ml IgG, and 10% DMSO. The activities of COX-1 and COX-2 were measured as described earlier (48) with 50 mum [1-14C]arachidonic acid (PerkinElmer) used as a substrate in 100 mm Tris-HCl, pH 8.0, containing 2 mum hematin, 5 mm l-tryptophan, 0.1 mg/ml IgG, and 10% DMSO. The products were separated by thin layer chromatography. The conversion rate from 14C-labeled substrate to 14C-labeled products was calculated by using an imaging plate system (Fuji Film, Tokyo, Japan). The kinetic constants were determined by Lineweaver-Burk plots prepared with SigmaPlot software (version 10.0 for Windows; Systat Software, Inc.).
###end p 22
###begin p 23
###xml 0 24 0 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NMR Titration Experiment</italic>
###xml 91 92 91 92 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 118 119 118 119 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 127 128 127 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref49">49</xref>
###xml 238 239 226 227 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 477 479 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref49">49</xref>
###xml 44 49 <span type="species:ncbi:10090">mouse</span>
NMR Titration Experiment-The NMR samples of mouse L-PGDS were prepared in a mixture of 50 mm sodium phosphate in 75% H2O, 15% D2O, 10% DMSO at pH 7.0, as reported previously (49). The protein concentration was adjusted to approximately1 mm in a 5-mm microcell NMR tube (Shigemi, Tokyo, Japan) for NMR experiments. NMR experiments were performed at 27.5 degreesC by using an INOVA600 spectrometer (Varian, Palo Alto, CA) equipped with shielded gradient triple resonance probes (49).
###end p 23
###begin p 24
###xml 65 67 65 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 116 117 116 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 119 121 119 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 190 191 190 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 197 199 197 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 408 411 400 403 <sub xmlns:xlink="http://www.w3.org/1999/xlink">tot</sub>
###xml 426 428 410 412 <sub xmlns:xlink="http://www.w3.org/1999/xlink">HN</sub>
###xml 431 432 415 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">W</italic>
###xml 432 434 416 418 <sub xmlns:xlink="http://www.w3.org/1999/xlink">HN</sub>
###xml 435 436 419 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 450 451 426 427 <sub xmlns:xlink="http://www.w3.org/1999/xlink">N</sub>
###xml 454 455 430 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">W</italic>
###xml 455 456 431 432 <sub xmlns:xlink="http://www.w3.org/1999/xlink">N</sub>
###xml 457 458 433 434 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 459 464 435 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#189;</sup>
###xml 482 484 446 448 <sub xmlns:xlink="http://www.w3.org/1999/xlink">HN</sub>
###xml 499 500 455 456 <sub xmlns:xlink="http://www.w3.org/1999/xlink">N</sub>
###xml 535 536 491 492 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 542 544 498 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 593 594 549 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">W</italic>
###xml 594 596 550 552 <sub xmlns:xlink="http://www.w3.org/1999/xlink">HN</sub>
###xml 605 606 561 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">W</italic>
###xml 606 607 562 563 <sub xmlns:xlink="http://www.w3.org/1999/xlink">N</sub>
The binding of L-PGDS to AT-56 was monitored by NMR titration of 15N-labeled L-PGDS with unlabeled ligands by using 1H-15N heteronuclear single quantum correlation experiments. The combined 1H and 15N chemical shift changes over the range of the titration from 0 to 2.0 equivalents of AT-56 were plotted. The composite chemical shift differences were calculated according to the empirical equation Deltadeltatot = {(DeltadeltaHN x WHN)2 + (DeltadeltaN x WN)2}(1/2), where DeltadeltaHN and DeltadeltaN are the chemical shift changes of 1H and 15N, respectively. The weighting factors used were WHN = 1 and WN = 0.2.
###end p 24
###begin p 25
###xml 0 31 0 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PG Production by Cultured Cells</italic>
###xml 212 213 212 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 245 246 245 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 401 404 401 404 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m l</sc>
###xml 511 512 510 511 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 604 605 597 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 692 694 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref50">50</xref>
###xml 50 55 <span type="species:ncbi:9606">human</span>
###xml 107 112 <span type="species:ncbi:9606">human</span>
###xml 384 390 <span type="species:ncbi:9913">bovine</span>
PG Production by Cultured Cells-L-PGDS-expressing human medulloblastoma TE-671 cells and H-PGDS-possessing human megakaryoblastic MEG-01S cells were purchased from American Type Culture Collection. TE-671 (1 x 106 cells/well) and MEG-01S (5 x 105/well) cells were seeded into multiplates and cultured in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum, 4 mm l-glutamine, 4.5 g/liter glucose, 100 units/ml penicillin, and 100 mug/ml streptomycin sulfate under a 5% CO2 atmosphere at 37 degreesC. MEG-01S cells were caused to differentiate by treatment with 12-O-tetradecanoylphorbol-13-acetate to express H-PGDS and COX-1, as described previously (50).
###end p 25
###begin p 26
###xml 112 113 111 112 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 247 248 239 240 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 339 340 325 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 533 535 513 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink">14</sup>
###xml 599 600 579 580 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 605 606 585 586 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 615 621 595 597 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2&#945;</sub>
After the cells had been cultured for 1 day, AT-56 was added to them at different doses ranging from 0 to 100 mum, and the cells were then incubated at 37 degreesC for 10 min. Thereafter, they were stimulated with a calcium ionophore, A23187 (5 mum), at 37 degreesC for 15 min. The culture media were harvested and centrifuged at 10,000 x g for 5 min to remove the cells, and the supernatant was removed and stored at -80 degreesC until the measurements of PGs could be made. In some experiments, these cells were prelabeled with [1-14C]arachidonic acid (3.7 kBq/well) for 12 h before the assay. PGD2, PGE2, and PGF2alpha in the culture medium were quantified as described below.
###end p 26
###begin p 27
###xml 0 40 0 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PG Production by Stab Wound Brain Injury</italic>
PG Production by Stab Wound Brain Injury-The protocols used for all animal experiments in this study were approved by the Animal Research Committee of the Osaka Bioscience Institute.
###end p 27
###begin p 28
###xml 83 84 83 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref51">51</xref>
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 260 264 <span type="species:ncbi:10090">mice</span>
###xml 423 427 <span type="species:ncbi:10090">mice</span>
H-PGDS KO mice (14-16-week-old males or females weighing 25-30 g, C57BL/6 strain) (2, 51) containing only L-PGDS were used for the stab injury model of the brain. AT-56 of various doses (1, 3, 10, and 30 mg/kg body weight) was administered orally to H-PGDS KO mice 1 h before the stab wound injury. Under pentobarbital (50 mg/kg) anesthesia, a 25-gauge needle was inserted into the frontal cortex of the brain of H-PGDS KO mice at a position 2 mm caudal to the bregma, 2 mm lateral to the sagittal suture, and 1 mm deep. After the needle had been withdrawn, the brains were harvested, immediately frozen in liquid nitrogen, and stored in a deep freezer (-80 degreesC) until the measurements of PG contents could be made.
###end p 28
###begin p 29
###xml 0 26 0 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Measurement of PG Contents</italic>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 262 263 262 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 268 269 268 269 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 272 273 272 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 278 279 278 279 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 286 287 286 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 292 298 292 294 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2&#945;</sub>
###xml 428 429 424 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 677 678 673 674 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 683 684 679 680 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 693 699 689 691 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2&#945;</sub>
Measurement of PG Contents-The amounts of PGs in the cell culture media and brain tissues were determined as described previously (22). In brief, the cell culture media and the frozen brain tissues were homogenized in ethanol containing 0.02% HCl at pH 2.0 and [3H]PGD2, [3H]PGE2, and [3H]PGF2alpha (PerkinElmer Life Sciences) as tracers to estimate the recovery during the purification procedure. After centrifugation at 500 x g for 20 min, the ethanol extracts were applied onto Sep-Pak C18 cartridges (Waters Associates, Milford, MA), washed with hexane, eluted with ethyl acetate, and fractionated by reverse-phase high performance liquid chromatography. The amounts of PGD2, PGE2, and PGF2alpha were measured by using their respective enzyme immunoassay kits (Cayman Chemical, Ann Arbor, MI), according to the manufacturer's instructions.
###end p 29
###begin p 30
###xml 0 44 0 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L-PGDS-mediated Allergic Airway Inflammation</italic>
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 401 403 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref52">52</xref>
###xml 518 520 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref52">52</xref>
###xml 45 50 <span type="species:ncbi:9606">Human</span>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
L-PGDS-mediated Allergic Airway Inflammation-Human L-PGDS-overexpressing TG mice (14-16-week-old males weighing 25-30 g, FVB strain (22)) were actively sensitized by an intraperitoneal injection of 10 mug of ovalbumin (Sigma) in 0.2 ml of aluminum hydroxide gel (Serva, Heidelberg, Germany) on days 0 and 14 and then exposed to aerosolized ovalbumin (50 mg/ml in sterile saline) for 20 min on day 21 (52). At 2 days after the ovalbumin challenge, the bronchoalveolar lavage fluid was collected as reported previously (52). Total and differential cell counts (500 cells) were obtained based on standard morphologic criteria after the cells had been cytospun onto glass slides and stained with Diff-Quik (Dade Diagnostics).
###end p 30
###begin p 31
###xml 0 25 0 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pharmacokinetics of AT-56</italic>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
###xml 244 248 <span type="species:ncbi:10090">mice</span>
Pharmacokinetics of AT-56-Male C57BL/6 mice (7 weeks old, weighing 22-26 g; Japan SLC, Shizuoka, Japan) were given a single oral dose of 10 mg/kg AT-56 or a single intravenous dose of 2 mg/kg AT-56. Plasma was collected after euthanasia from 3 mice/group at 30 min and 1, 2, 4, 8, and 24 h for oral administration and 5 and 30 min and 1, 2, 4, 8, 12, and 24 h after intravenous dosing. Whole blood sample was collected into a heparinized syringe at each time point. Plasma was obtained by centrifugation and was stored at -30 degreesC until analysis.
###end p 31
###begin p 32
###xml 885 886 866 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">m</italic>
###xml 887 888 868 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink">z</italic>
Concentrations of AT-56 in plasma were determined by high performance liquid chromatography coupled to mass spectrometry. Samples were separated by chromatography with a Cadenza HS-C18 column (2 mm x 150 mm; Imtact Corp., Kyoto, Japan) at a column temperature of 33 degreesC with a 5-90% acetonitrile gradient in 0.02% formic acid at a flow rate of 0.2 ml/min for 12 min. Injection volume was 10 mul. AT-56 was detected by mass spectrometry with the system (Waters Associates) composed of the 2695 separation module, 996 photodiode array detector, and ZQ-4000 mass spectrometry detector with an electrospray ionization source. The electrospray ionization interface was operated at a source temperature of 115 degreesC and a desolvation temperature of 350 degreesC. Cone gas and desolvation gas flow were 124 and 606 liters/h, respectively. Cone voltage for AT-56 was positive 33 V for m/z = 398. Pharmacokinetic parameters were calculated using noncompartmental analysis with WinNonlin, version 5.0.1 (Pharsight, Mountain View, CA).
###end p 32
###begin p 33
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Statistics</italic>
###xml 139 140 139 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Statistics-Comparisons were analyzed for statistical significance by Dunnett's multicomparison test using SigmaPlot (Systat Software, CA). p < 0.05 was considered significant.
###end p 33
###begin title 34
RESULTS
###end title 34
###begin p 35
###xml 0 42 0 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inhibition of the L-PGDS Activity by AT-56</italic>
###xml 205 206 201 202 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 299 300 294 295 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 318 320 313 315 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 353 354 347 348 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 511 512 504 505 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 520 521 513 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 514 521 507 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 110 115 <span type="species:ncbi:9606">human</span>
###xml 145 150 <span type="species:ncbi:10090">mouse</span>
Inhibition of the L-PGDS Activity by AT-56-AT-56 inhibited the PGDS activity of both beta-trace purified from human CSF and purified recombinant mouse L-PGDS C89A/C186A mutant in a concentration (10-250 mum)-dependent manner. The L-PGDS activity of both preparations was inhibited to 30% with 250 mum AT-56, and the IC50 value was calculated to be 95 mum. However, the activities of the purified COX-1, COX-2, m-PGES-1, or H-PGDS in the arachidonate cascade were not significantly affected by AT-56 up to 250 mum (Fig. 2A).
###end p 35
###begin p 36
###xml 122 123 122 123 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 166 167 166 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 160 167 160 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 183 184 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V</italic>
###xml 184 187 184 187 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 222 223 222 223 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 221 223 221 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 292 293 291 292 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 310 311 309 310 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 309 311 308 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>i</sub></italic>
###xml 353 354 351 352 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 392 393 390 391 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 391 393 389 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 430 431 428 429 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 438 439 435 436 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
Kinetic experiments revealed that AT-56 inhibited the recombinant L-PGDS in a competitive manner against the substrate PGH2, as shown in Lineweaver-Burk plots (Fig. 2B), in which the Vmax value remained unchanged but the Km value increased when the AT-56 concentration was increased (0-120 mum). The apparent Ki value of AT-56 was calculated to be 75 mum, which was 5.3-fold higher than the Km value of the L-PGDS activity for PGH2 (14 mum) in the presence of 10% DMSO.
###end p 36
###begin p 37
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 2.</label>
###xml 9 48 9 48 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Specific inhibition of L-PGDS by AT-56.</bold>
###xml 48 49 48 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 189 190 185 186 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 194 195 190 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 203 204 199 200 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 260 261 249 250 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 335 336 323 324 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 381 382 368 369 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 390 391 377 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 517 518 504 505 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 527 528 513 514 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 536 537 522 523 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 562 563 548 549 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 636 637 616 617 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 9 686 9 640 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="38"><bold>Specific inhibition of L-PGDS by AT-56.</bold><italic>A</italic>, human CSF L-PGDS (&#946;-trace), the recombinant mouse L-PGDS C89A/C186A mutant, the purified m-PGES-1, and H-PGDS were incubated with 10 &#956;<sc>m</sc> PGH<sub>2</sub> and 1 m<sc>m</sc> GSH at 25 &#176;C for 30 s in the presence of 0&#8211;250 &#956;<sc>m</sc> AT-56 in 10% DMSO. The purified COX-1 and COX-2 were incubated with 50 &#956;<sc>m</sc> arachidonic acid in the presence of 0&#8211;250 &#956;<sc>m</sc> AT-56. <italic>B</italic>, Lineweaver-Burk plot for L-PGDS. Recombinant mouse L-PGDS C89A/C186A mutant was incubated with various concentrations of PGH<sub>2</sub> (3&#8211;20 &#956;<sc>m</sc>), 100 m<sc>m</sc> Tris-HCl (pH 8), and 1 m<sc>m</sc> dithiothreitol in the presence of 0 (&#9675;), 40 (&#8226;), 100 (&#9633;), or 120 &#956;<sc>m</sc> (&#9642;) AT-56 in 10% DMSO.</p>
###xml 9 686 9 640 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="38"><bold>Specific inhibition of L-PGDS by AT-56.</bold><italic>A</italic>, human CSF L-PGDS (&#946;-trace), the recombinant mouse L-PGDS C89A/C186A mutant, the purified m-PGES-1, and H-PGDS were incubated with 10 &#956;<sc>m</sc> PGH<sub>2</sub> and 1 m<sc>m</sc> GSH at 25 &#176;C for 30 s in the presence of 0&#8211;250 &#956;<sc>m</sc> AT-56 in 10% DMSO. The purified COX-1 and COX-2 were incubated with 50 &#956;<sc>m</sc> arachidonic acid in the presence of 0&#8211;250 &#956;<sc>m</sc> AT-56. <italic>B</italic>, Lineweaver-Burk plot for L-PGDS. Recombinant mouse L-PGDS C89A/C186A mutant was incubated with various concentrations of PGH<sub>2</sub> (3&#8211;20 &#956;<sc>m</sc>), 100 m<sc>m</sc> Tris-HCl (pH 8), and 1 m<sc>m</sc> dithiothreitol in the presence of 0 (&#9675;), 40 (&#8226;), 100 (&#9633;), or 120 &#956;<sc>m</sc> (&#9642;) AT-56 in 10% DMSO.</p></caption>
###xml 686 686 640 640 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0140969560002"/>
###xml 0 686 0 640 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig2"><label>FIGURE 2.</label><caption><p textid="38"><bold>Specific inhibition of L-PGDS by AT-56.</bold><italic>A</italic>, human CSF L-PGDS (&#946;-trace), the recombinant mouse L-PGDS C89A/C186A mutant, the purified m-PGES-1, and H-PGDS were incubated with 10 &#956;<sc>m</sc> PGH<sub>2</sub> and 1 m<sc>m</sc> GSH at 25 &#176;C for 30 s in the presence of 0&#8211;250 &#956;<sc>m</sc> AT-56 in 10% DMSO. The purified COX-1 and COX-2 were incubated with 50 &#956;<sc>m</sc> arachidonic acid in the presence of 0&#8211;250 &#956;<sc>m</sc> AT-56. <italic>B</italic>, Lineweaver-Burk plot for L-PGDS. Recombinant mouse L-PGDS C89A/C186A mutant was incubated with various concentrations of PGH<sub>2</sub> (3&#8211;20 &#956;<sc>m</sc>), 100 m<sc>m</sc> Tris-HCl (pH 8), and 1 m<sc>m</sc> dithiothreitol in the presence of 0 (&#9675;), 40 (&#8226;), 100 (&#9633;), or 120 &#956;<sc>m</sc> (&#9642;) AT-56 in 10% DMSO.</p></caption><graphic xlink:href="zbc0140969560002"/></fig>
###xml 51 56 <span type="species:ncbi:9606">human</span>
###xml 98 103 <span type="species:ncbi:10090">mouse</span>
###xml 438 443 <span type="species:ncbi:10090">mouse</span>
FIGURE 2.Specific inhibition of L-PGDS by AT-56.A, human CSF L-PGDS (beta-trace), the recombinant mouse L-PGDS C89A/C186A mutant, the purified m-PGES-1, and H-PGDS were incubated with 10 mum PGH2 and 1 mm GSH at 25 degreesC for 30 s in the presence of 0-250 mum AT-56 in 10% DMSO. The purified COX-1 and COX-2 were incubated with 50 mum arachidonic acid in the presence of 0-250 mum AT-56. B, Lineweaver-Burk plot for L-PGDS. Recombinant mouse L-PGDS C89A/C186A mutant was incubated with various concentrations of PGH2 (3-20 mum), 100 mm Tris-HCl (pH 8), and 1 mm dithiothreitol in the presence of 0 (o), 40 (*), 100 (square), or 120 mum (blacksquare, square, filled) AT-56 in 10% DMSO.
###end p 37
###begin p 38
###xml 0 39 0 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Specific inhibition of L-PGDS by AT-56.</bold>
###xml 39 40 39 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 180 181 176 177 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 185 186 181 182 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 194 195 190 191 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 251 252 240 241 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 326 327 314 315 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 372 373 359 360 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 381 382 368 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 508 509 495 496 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 518 519 504 505 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 527 528 513 514 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 553 554 539 540 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 627 628 607 608 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 89 94 <span type="species:ncbi:10090">mouse</span>
###xml 429 434 <span type="species:ncbi:10090">mouse</span>
Specific inhibition of L-PGDS by AT-56.A, human CSF L-PGDS (beta-trace), the recombinant mouse L-PGDS C89A/C186A mutant, the purified m-PGES-1, and H-PGDS were incubated with 10 mum PGH2 and 1 mm GSH at 25 degreesC for 30 s in the presence of 0-250 mum AT-56 in 10% DMSO. The purified COX-1 and COX-2 were incubated with 50 mum arachidonic acid in the presence of 0-250 mum AT-56. B, Lineweaver-Burk plot for L-PGDS. Recombinant mouse L-PGDS C89A/C186A mutant was incubated with various concentrations of PGH2 (3-20 mum), 100 mm Tris-HCl (pH 8), and 1 mm dithiothreitol in the presence of 0 (o), 40 (*), 100 (square), or 120 mum (blacksquare, square, filled) AT-56 in 10% DMSO.
###end p 38
###begin p 39
###xml 0 60 0 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Binding Interaction between L-PGDS and AT-56 Analyzed by NMR</italic>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref49">49</xref>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref53">53</xref>
###xml 288 289 288 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 291 293 291 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 398 404 398 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 527 531 527 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e.</italic>
###xml 535 537 535 537 <sup xmlns:xlink="http://www.w3.org/1999/xlink">52</sup>
###xml 542 544 542 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink">80</sup>
###xml 549 551 549 551 <sup xmlns:xlink="http://www.w3.org/1999/xlink">94</sup>
###xml 560 563 560 563 <sup xmlns:xlink="http://www.w3.org/1999/xlink">116</sup>
###xml 572 573 572 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 566 573 566 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 731 732 728 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 725 732 722 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 751 752 748 749 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 804 806 801 803 <sup xmlns:xlink="http://www.w3.org/1999/xlink">65</sup>
###xml 819 821 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref49">49</xref>
###xml 998 1000 995 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref49">49</xref>
###xml 116 121 <span type="species:ncbi:10090">mouse</span>
Binding Interaction between L-PGDS and AT-56 Analyzed by NMR-We have previously determined the NMR structure of the mouse L-PGDS C89A/C186A mutant (49). The interaction sites of L-PGDS with AT-56 were determined by the chemical shift perturbation method (53) based on the two-dimensional 1H-15N heteronuclear single quantum correlation NMR spectra of L-PGDS after the successive addition of AT-56 (Fig. 3). Upon AT-56 binding, large changes (>0.08 ppm) of chemical shift were observed at several amino acid residues of L-PGDS (i.e. Ser52, Thr80, Met94, and His116) (Fig. 3A). These residues are located at the upper part of the central cavity of the beta-barrel structure of the L-PGDS molecule (Protein Data Bank code 2E4J; Fig. 3B), in which the PGH2-binding site containing the catalytic center of Cys65 is located (49). However, the AT-56 binding did not cause any significant chemical shift in the regions of the retinoic acid-binding pocket at the lower part of the central cavity of L-PGDS (49).
###end p 39
###begin p 40
###xml 0 61 0 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fluorescence Quenching Study on L-PGDS after Binding of AT-56</italic>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref49">49</xref>
###xml 533 534 533 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 527 534 527 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 655 656 654 655 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 875 876 873 874 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 890 891 888 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 884 891 882 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 967 971 965 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-cis</italic>
###xml 1107 1108 1104 1105 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1111 1115 1108 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-cis</italic>
###xml 1137 1138 1134 1135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1131 1138 1128 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 1187 1188 1183 1184 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1321 1322 1316 1317 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1407 1411 1402 1406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-cis</italic>
###xml 1494 1495 1488 1489 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1498 1502 1492 1496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-cis</italic>
###xml 1593 1594 1586 1587 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1650 1652 1643 1645 <sup xmlns:xlink="http://www.w3.org/1999/xlink">54</sup>
###xml 1696 1698 1689 1691 <sup xmlns:xlink="http://www.w3.org/1999/xlink">43</sup>
###xml 181 186 <span type="species:ncbi:10090">mouse</span>
###xml 223 228 <span type="species:ncbi:10090">Mouse</span>
###xml 458 463 <span type="species:ncbi:10090">mouse</span>
Fluorescence Quenching Study on L-PGDS after Binding of AT-56-To confirm the mode of binding of AT-56 to L-PGDS, we examined the fluorescence quenching of intrinsic Trp residues of mouse L-PGDS after incubation with AT-56. Mouse L-PGDS contains two tryptophan residues, at positions 43 and 54, the former of which is located at the bottom of barrel and the latter in the AB-loop at the entrance of the central cavity of L-PGDS (49). The C89A/C186A mutant of mouse L-PGDS showed fluorescence quenching by the addition of AT-56 (Fig. 4A) in a concentration-dependent manner, and the fluorescence intensity was decreased to about 60% in the presence of 10 mum AT-56. On the other hand, the W54A/C89A/C186A mutant showed about 60% of the tryptophan fluorescence of the C89A/C186A mutant in the absence of AT-56 and did not show the fluorescence quenching in the presence of 10 mum AT-56 (Fig. 4A). The C89A/C186A mutant showed fluorescence quenching by the addition of 13-cis-retinoic acid in a concentration-dependent manner, with the fluorescence intensity being decreased to about 8% in the presence of 10 mum 13-cis-retinoic acid (Fig. 4B). The C89A/C186A mutant in the presence of 10 mum AT-56 and the W54A/C89A/C186A mutant showed about 60% of the fluorescence intensity of the C89A/C186A mutant in the absence of 10 mum AT-56. In both cases, the fluorescence intensity was decreased by the addition of 13-cis-retinoic acid in a concentration-dependent manner to <10% in the presence of 10 mum 13-cis-retinoic acid, giving the same fluorescence quenching curves even in the presence of 10 mum AT-56. These results indicate that AT-56 binds near Trp54 in the AB-loop of L-PGDS but not to the Trp43 residue in the retinoid-binding pocket, being consistent with the results obtained by NMR titration analysis.
###end p 40
###begin p 41
###xml 17 18 17 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 0 94 0 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inhibition of PGD<sub>2</sub> Production in L-PGDS-expressing Human Medulloblastoma TE-671 Cells by AT-56</italic>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref54">54</xref>
###xml 219 220 218 219 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 279 280 277 278 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 350 351 342 343 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 356 357 348 349 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 366 372 358 360 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2&#945;</sub>
###xml 518 519 506 507 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 559 560 547 548 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 568 574 556 558 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2&#945;</sub>
###xml 582 583 566 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 576 583 560 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 51 56 <span type="species:ncbi:9606">Human</span>
###xml 95 100 <span type="species:ncbi:9606">Human</span>
Inhibition of PGD2 Production in L-PGDS-expressing Human Medulloblastoma TE-671 Cells by AT-56-Human medulloblastoma TE-671 cells constitutively express L-PGDS (54). We pretreated TE-671 cells for 10 min with 0 to 30 mum AT-56, stimulated them with calcium ionophore A23187 (5 mum) at 37 degreesC for 15 min, and then determined the production of PGD2, PGE2, and PGF2alpha by enzyme immunoassay to investigate the effects of AT-56 on PG production by these cells. AT-56 dose-dependently inhibited the production of PGD2 without affecting the production of PGE2 and PGF2alpha (Fig. 5A).
###end p 41
###begin p 42
###xml 51 52 51 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 82 83 81 82 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 116 118 115 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">14</sup>
###xml 168 169 167 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 162 169 161 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 205 207 204 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink">14</sup>
###xml 268 269 266 267 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 325 326 323 324 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 369 371 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref50">50</xref>
###xml 422 423 420 421 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 539 540 537 538 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 330 335 <span type="species:ncbi:9606">human</span>
Dose-dependent inhibition of the A23187-induced PGD2 production by AT-56 (3-100 mum) was also confirmed by using [1-14C]arachidonic acid-prelabeled TE-671 cells (Fig. 5B). However, the production of other 14C-labeled metabolites was not inhibited by AT-56 up to 100 mum. Moreover, AT-56 had no effect on the production of PGD2 by human H-PGDS-expressing MEG-01S cells (50). H-PGDS-specific inhibitor, HQL-79, inhibited PGD2 production from MEG-01S cells but not from TE-671 cells. These results indicate that AT-56 selectively inhibits PGD2 production catalyzed by L-PGDS without affecting the production of other prostanoids.
###end p 42
###begin p 43
###xml 18 19 18 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 0 88 0 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Suppression of PGD<sub>2</sub> Production in the Stab-wounded Brain by Oral Administration of AT-56</italic>
###xml 124 131 124 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref51">51</xref>
###xml 255 256 255 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 540 541 536 537 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 616 617 612 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 610 617 606 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>A</italic></xref>
###xml 638 639 634 635 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 647 653 643 645 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2&#945;</sub>
###xml 723 724 715 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 717 724 709 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>A</italic></xref>
###xml 151 155 <span type="species:ncbi:10090">mice</span>
###xml 303 307 <span type="species:ncbi:10090">mice</span>
###xml 395 399 <span type="species:ncbi:10090">mice</span>
Suppression of PGD2 Production in the Stab-wounded Brain by Oral Administration of AT-56-To investigate the effect of AT-56 in vivo, we used H-PGDS KO mice, which express only L-PGDS in all of their organs (51). In a stab wound brain injury model, the PGD2 content in the brain of the wounded H-PGDS KO mice (118 +/- 22 ng/brain) was significantly increased as compared with that of the control mice without injury (0.23 +/- 0.04 ng/brain). When various doses of AT-56 were administered orally 1 h before the injury, the total amount of PGD2 in the brain decreased dose-dependently to 40% with 30 mg/kg AT-56 (Fig. 6A). The amounts of PGE2 and PGF2alpha in the brain were not significantly changed in any conditions (Fig. 6A). These results indicate that orally administered AT-56 inhibited the L-PGDS reaction in the brain.
###end p 43
###begin p 44
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 3.</label>
###xml 9 62 9 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Interactions of L-PGDS with AT-56 as examined by NMR.</bold>
###xml 62 63 62 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 75 76 75 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 82 84 82 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 114 123 114 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">delta ppm</italic>
###xml 125 131 125 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 203 204 203 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 259 280 259 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ribbon representation</italic>
###xml 290 296 290 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panels</italic>
###xml 388 391 386 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 483 491 475 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sky blue</italic>
###xml 496 497 488 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 564 570 556 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">shaded</italic>
###xml 574 578 566 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pink</italic>
###xml 9 579 9 571 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="45"><bold>Interactions of L-PGDS with AT-56 as examined by NMR.</bold><italic>A</italic>, composite <sup>1</sup>H and <sup>15</sup>N chemical shift differences (<italic>delta ppm</italic>) <italic>versus</italic> the amino acid sequence of recombinant mouse L-PGDS C89A/C186A mutant. <italic>B</italic>, overall structure of L-PGDS after AT-56 binding in a <italic>ribbon representation</italic>. In both <italic>panels</italic>, the residues with relatively large changes in chemical shift (&#8805;0.08) are represented in <italic>red</italic>, whereas residues with shifts in the middle range (0.06 &#8804; &#916; ppm &lt; 0.08) are shown in <italic>sky blue</italic>. In <italic>B</italic>, the AT-56-binding site predicted from NMR signal perturbation is <italic>shaded</italic> in <italic>pink</italic>.</p>
###xml 9 579 9 571 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="45"><bold>Interactions of L-PGDS with AT-56 as examined by NMR.</bold><italic>A</italic>, composite <sup>1</sup>H and <sup>15</sup>N chemical shift differences (<italic>delta ppm</italic>) <italic>versus</italic> the amino acid sequence of recombinant mouse L-PGDS C89A/C186A mutant. <italic>B</italic>, overall structure of L-PGDS after AT-56 binding in a <italic>ribbon representation</italic>. In both <italic>panels</italic>, the residues with relatively large changes in chemical shift (&#8805;0.08) are represented in <italic>red</italic>, whereas residues with shifts in the middle range (0.06 &#8804; &#916; ppm &lt; 0.08) are shown in <italic>sky blue</italic>. In <italic>B</italic>, the AT-56-binding site predicted from NMR signal perturbation is <italic>shaded</italic> in <italic>pink</italic>.</p></caption>
###xml 579 579 571 571 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0140969560003"/>
###xml 0 579 0 571 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig3"><label>FIGURE 3.</label><caption><p textid="45"><bold>Interactions of L-PGDS with AT-56 as examined by NMR.</bold><italic>A</italic>, composite <sup>1</sup>H and <sup>15</sup>N chemical shift differences (<italic>delta ppm</italic>) <italic>versus</italic> the amino acid sequence of recombinant mouse L-PGDS C89A/C186A mutant. <italic>B</italic>, overall structure of L-PGDS after AT-56 binding in a <italic>ribbon representation</italic>. In both <italic>panels</italic>, the residues with relatively large changes in chemical shift (&#8805;0.08) are represented in <italic>red</italic>, whereas residues with shifts in the middle range (0.06 &#8804; &#916; ppm &lt; 0.08) are shown in <italic>sky blue</italic>. In <italic>B</italic>, the AT-56-binding site predicted from NMR signal perturbation is <italic>shaded</italic> in <italic>pink</italic>.</p></caption><graphic xlink:href="zbc0140969560003"/></fig>
###xml 171 176 <span type="species:ncbi:10090">mouse</span>
FIGURE 3.Interactions of L-PGDS with AT-56 as examined by NMR.A, composite 1H and 15N chemical shift differences (delta ppm) versus the amino acid sequence of recombinant mouse L-PGDS C89A/C186A mutant. B, overall structure of L-PGDS after AT-56 binding in a ribbon representation. In both panels, the residues with relatively large changes in chemical shift (>/=0.08) are represented in red, whereas residues with shifts in the middle range (0.06 </= Delta ppm < 0.08) are shown in sky blue. In B, the AT-56-binding site predicted from NMR signal perturbation is shaded in pink.
###end p 44
###begin p 45
###xml 0 53 0 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Interactions of L-PGDS with AT-56 as examined by NMR.</bold>
###xml 53 54 53 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 73 75 73 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 105 114 105 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">delta ppm</italic>
###xml 116 122 116 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 194 195 194 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 250 271 250 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ribbon representation</italic>
###xml 281 287 281 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panels</italic>
###xml 379 382 377 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 474 482 466 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sky blue</italic>
###xml 487 488 479 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 555 561 547 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">shaded</italic>
###xml 565 569 557 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pink</italic>
###xml 162 167 <span type="species:ncbi:10090">mouse</span>
Interactions of L-PGDS with AT-56 as examined by NMR.A, composite 1H and 15N chemical shift differences (delta ppm) versus the amino acid sequence of recombinant mouse L-PGDS C89A/C186A mutant. B, overall structure of L-PGDS after AT-56 binding in a ribbon representation. In both panels, the residues with relatively large changes in chemical shift (>/=0.08) are represented in red, whereas residues with shifts in the middle range (0.06 </= Delta ppm < 0.08) are shown in sky blue. In B, the AT-56-binding site predicted from NMR signal perturbation is shaded in pink.
###end p 45
###begin p 46
###xml 0 68 0 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Suppression of L-PGDS-mediated Allergic Airway Inflammation by AT-56</italic>
###xml 125 126 125 126 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref52">52</xref>
###xml 480 481 474 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 652 653 640 641 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 821 822 803 804 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 854 855 836 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 848 855 830 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>B</italic></xref>
###xml 971 978 953 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 155 160 <span type="species:ncbi:9606">Human</span>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
###xml 575 579 <span type="species:ncbi:10090">mice</span>
###xml 764 768 <span type="species:ncbi:10090">mice</span>
###xml 958 963 <span type="species:ncbi:9606">human</span>
Suppression of L-PGDS-mediated Allergic Airway Inflammation by AT-56-We next evaluated the therapeutic effect of AT-56 on PGD2-mediated lung inflammation. Human L-PGDS TG mice were used in an OVA-induced lung inflammation model (52). The numbers of total cells and infiltrating eosinophils and monocytes in the bronchoalveolar lavage fluid of the L-PGDS TG mice were dose-dependently decreased to 75, 50, and 96% (actual numbers: 8.7 +/- 1.9, 2.53 +/- 0.73, and 6.16 +/- 1.14 x 104 cells/ml for total cells, eosinophils, and monocytes, respectively) in 1 mg/kg AT-56-treated mice and to 23, 6, and 41% (2.7 +/- 0.4, 0.31 +/- 0.14, and 2.59 +/- 0.3 x 104 cells/ml, respectively) in 10 mg/kg AT-56-treated ones compared with the numbers for the vehicle-administered mice (11.6 +/- 1.6, 5.28 +/- 1.37, and 6.36 +/- 0.72 x 104 cells/ml, respectively) (Fig. 6B). These results demonstrate that AT-56 prevented the eosinophil infiltration by inhibiting transgened human L-PGDS in vivo.
###end p 46
###begin p 47
###xml 0 35 0 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pharmacokinetic Properties of AT-56</italic>
###xml 92 98 92 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 265 272 265 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table 1</xref>
###xml 191 195 <span type="species:ncbi:10090">mice</span>
###xml 861 865 <span type="species:ncbi:10090">mice</span>
Pharmacokinetic Properties of AT-56-We also determined pharmacokinetic properties of AT-56. Fig. 7 shows the time courses of the plasma concentration of AT-56 after an oral administration to mice at a dose of 10 mg/kg and an intravenous bolus injection of 2 mg/kg. Table 1 summarizes pharmacokinetic parameters of AT-56. After the oral administration, the plasma level of AT-56 reached the maximum (2.15 mug/ml) within 30 min and decreased with time to be lower than the detection limit (0.4 ng/ml) at 12 h after the administration. The area under the concentration-time curve was calculated to be 2.18 and 8.95 mug/ml x h after the intravenous administration of 2 mg/kg and the oral administration of 10 mg/kg, respectively. Based on these data, bioavailability of AT-56 was calculated to be 82%, indicating that orally administered AT-56 was well absorbed in mice.
###end p 47
###begin p 48
###xml 0 7 0 7 <label xmlns:xlink="http://www.w3.org/1999/xlink">TABLE 1</label>
###xml 7 42 7 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Pharmacokinetic parameters of AT-56</bold>
###xml 7 42 7 42 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="49"><bold>Pharmacokinetic parameters of AT-56</bold></p>
###xml 7 42 7 42 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="49"><bold>Pharmacokinetic parameters of AT-56</bold></p></caption>
###xml 42 47 42 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Route</bold>
###xml 42 47 42 47 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Route</bold></th>
###xml 47 51 47 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Dose</bold>
###xml 47 51 47 51 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Dose</bold></th>
###xml 51 54 51 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink">AUC</bold>
###xml 54 55 54 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 54 55 54 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref>
###xml 51 55 51 55 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>AUC</bold><xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref></th>
###xml 55 56 55 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 56 59 56 59 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 55 59 55 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>C</italic><sub>max</sub></bold>
###xml 59 60 59 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 59 60 59 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table-fn" rid="tblfn2"><italic>b</italic></xref>
###xml 55 60 55 60 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold><italic>C</italic><sub>max</sub></bold><xref ref-type="table-fn" rid="tblfn2"><italic>b</italic></xref></th>
###xml 60 61 60 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 61 62 61 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 60 62 60 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>C</italic><sub>0</sub></bold>
###xml 62 63 62 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 62 63 62 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table-fn" rid="tblfn3"><italic>c</italic></xref>
###xml 60 63 60 63 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold><italic>C</italic><sub>0</sub></bold><xref ref-type="table-fn" rid="tblfn3"><italic>c</italic></xref></th>
###xml 63 64 63 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 64 67 64 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 63 67 63 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>t</italic><sub>max</sub></bold>
###xml 67 68 67 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 67 68 67 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table-fn" rid="tblfn4"><italic>d</italic></xref>
###xml 63 68 63 68 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold><italic>t</italic><sub>max</sub></bold><xref ref-type="table-fn" rid="tblfn4"><italic>d</italic></xref></th>
###xml 68 69 68 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 69 74 69 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#189;</sub>
###xml 68 74 68 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>t</italic><sub>&#189;</sub></bold>
###xml 74 75 70 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e</italic>
###xml 74 75 70 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table-fn" rid="tblfn5"><italic>e</italic></xref>
###xml 68 75 68 71 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold><italic>t</italic><sub>&#189;</sub></bold><xref ref-type="table-fn" rid="tblfn5"><italic>e</italic></xref></th>
###xml 75 77 71 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink">BA</bold>
###xml 77 78 73 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">f</italic>
###xml 77 78 73 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table-fn" rid="tblfn6"><italic>f</italic></xref>
###xml 75 78 71 74 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>BA</bold><xref ref-type="table-fn" rid="tblfn6"><italic>f</italic></xref></th>
###xml 42 78 42 74 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th colspan="1" rowspan="1" align="center" valign="top"><bold>Route</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Dose</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>AUC</bold><xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>C</italic><sub>max</sub></bold><xref ref-type="table-fn" rid="tblfn2"><italic>b</italic></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>C</italic><sub>0</sub></bold><xref ref-type="table-fn" rid="tblfn3"><italic>c</italic></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>t</italic><sub>max</sub></bold><xref ref-type="table-fn" rid="tblfn4"><italic>d</italic></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>t</italic><sub>&#189;</sub></bold><xref ref-type="table-fn" rid="tblfn5"><italic>e</italic></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>BA</bold><xref ref-type="table-fn" rid="tblfn6"><italic>f</italic></xref></th></tr>
###xml 42 78 42 74 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Route</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Dose</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>AUC</bold><xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>C</italic><sub>max</sub></bold><xref ref-type="table-fn" rid="tblfn2"><italic>b</italic></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>C</italic><sub>0</sub></bold><xref ref-type="table-fn" rid="tblfn3"><italic>c</italic></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>t</italic><sub>max</sub></bold><xref ref-type="table-fn" rid="tblfn4"><italic>d</italic></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>t</italic><sub>&#189;</sub></bold><xref ref-type="table-fn" rid="tblfn5"><italic>e</italic></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>BA</bold><xref ref-type="table-fn" rid="tblfn6"><italic>f</italic></xref></th></tr></thead>
###xml 78 78 74 74 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"/>
###xml 78 83 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mg/kg</italic>
###xml 78 83 74 79 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"><italic>mg/kg</italic></td>
###xml 83 91 79 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#956;g&#183;h/ml</italic>
###xml 83 91 79 86 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><italic>&#956;g&#183;h/ml</italic></td>
###xml 91 97 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#956;g/ml</italic>
###xml 91 97 86 91 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><italic>&#956;g/ml</italic></td>
###xml 97 103 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#956;g/ml</italic>
###xml 97 103 91 96 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><italic>&#956;g/ml</italic></td>
###xml 103 104 96 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">h</italic>
###xml 103 104 96 97 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><italic>h</italic></td>
###xml 104 105 97 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">h</italic>
###xml 104 105 97 98 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><italic>h</italic></td>
###xml 105 106 98 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">%</italic>
###xml 105 106 98 99 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><italic>%</italic></td>
###xml 78 106 74 99 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"><italic>mg/kg</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>&#956;g&#183;h/ml</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>&#956;g/ml</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>&#956;g/ml</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>h</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>h</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>%</italic></td></tr>
###xml 106 119 99 112 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Intravenous </td>
###xml 119 122 112 115 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> 2 </td>
###xml 122 128 115 121 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 1.28 </td>
###xml 128 128 121 121 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"/>
###xml 128 134 121 127 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.86 </td>
###xml 134 140 127 133 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.08 </td>
###xml 140 146 133 139 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 2.35 </td>
###xml 146 146 139 139 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"/>
###xml 106 146 99 139 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Intravenous </td><td colspan="1" rowspan="1" align="right" valign="top"> 2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.28 </td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 0.86 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.08 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.35 </td><td colspan="1" rowspan="1" align="center" valign="top"/></tr>
###xml 146 152 139 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Per os</italic>
###xml 146 152 139 145 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"><italic>Per os</italic></td>
###xml 152 156 145 149 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="right" valign="top"> 10 </td>
###xml 156 162 149 155 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 8.95 </td>
###xml 162 168 155 161 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 2.15 </td>
###xml 168 168 161 161 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"/>
###xml 168 174 161 167 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 0.50 </td>
###xml 174 180 167 173 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 1.71 </td>
###xml 180 186 173 179 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> 82.0 </td>
###xml 146 186 139 179 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"><italic>Per os</italic></td><td colspan="1" rowspan="1" align="right" valign="top"> 10 </td><td colspan="1" rowspan="1" align="center" valign="top"> 8.95 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.15 </td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 0.50 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.71 </td><td colspan="1" rowspan="1" align="center" valign="top"> 82.0 </td></tr>
###xml 78 186 74 179 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"><italic>mg/kg</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>&#956;g&#183;h/ml</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>&#956;g/ml</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>&#956;g/ml</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>h</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>h</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>%</italic></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Intravenous </td><td colspan="1" rowspan="1" align="right" valign="top"> 2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.28 </td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 0.86 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.08 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.35 </td><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"><italic>Per os</italic></td><td colspan="1" rowspan="1" align="right" valign="top"> 10 </td><td colspan="1" rowspan="1" align="center" valign="top"> 8.95 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.15 </td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 0.50 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.71 </td><td colspan="1" rowspan="1" align="center" valign="top"> 82.0 </td></tr></tbody>
###xml 42 186 42 179 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Route</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Dose</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>AUC</bold><xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>C</italic><sub>max</sub></bold><xref ref-type="table-fn" rid="tblfn2"><italic>b</italic></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>C</italic><sub>0</sub></bold><xref ref-type="table-fn" rid="tblfn3"><italic>c</italic></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>t</italic><sub>max</sub></bold><xref ref-type="table-fn" rid="tblfn4"><italic>d</italic></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>t</italic><sub>&#189;</sub></bold><xref ref-type="table-fn" rid="tblfn5"><italic>e</italic></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>BA</bold><xref ref-type="table-fn" rid="tblfn6"><italic>f</italic></xref></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"><italic>mg/kg</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>&#956;g&#183;h/ml</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>&#956;g/ml</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>&#956;g/ml</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>h</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>h</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>%</italic></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Intravenous </td><td colspan="1" rowspan="1" align="right" valign="top"> 2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.28 </td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 0.86 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.08 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.35 </td><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"><italic>Per os</italic></td><td colspan="1" rowspan="1" align="right" valign="top"> 10 </td><td colspan="1" rowspan="1" align="center" valign="top"> 8.95 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.15 </td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 0.50 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.71 </td><td colspan="1" rowspan="1" align="center" valign="top"> 82.0 </td></tr></tbody></table>
###xml 186 187 179 180 <label xmlns:xlink="http://www.w3.org/1999/xlink">a</label>
###xml 221 227 214 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 187 282 180 275 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="50">AUC, area under the concentration <italic>versus</italic> time curve from 0 to the last quantifiable time point.</p>
###xml 186 282 179 275 <fn xmlns:xlink="http://www.w3.org/1999/xlink" id="tblfn1"><label>a</label><p textid="50">AUC, area under the concentration <italic>versus</italic> time curve from 0 to the last quantifiable time point.</p></fn>
###xml 282 283 275 276 <label xmlns:xlink="http://www.w3.org/1999/xlink">b</label>
###xml 283 284 276 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 284 287 277 280 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 283 311 276 304 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="51"><italic>C</italic><sub>max</sub>, maximal concentration.</p>
###xml 282 311 275 304 <fn xmlns:xlink="http://www.w3.org/1999/xlink" id="tblfn2"><label>b</label><p textid="51"><italic>C</italic><sub>max</sub>, maximal concentration.</p></fn>
###xml 311 312 304 305 <label xmlns:xlink="http://www.w3.org/1999/xlink">c</label>
###xml 312 313 305 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 313 314 306 307 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 312 338 305 331 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="52"><italic>C</italic><sub>0</sub>, initial concentration.</p>
###xml 311 338 304 331 <fn xmlns:xlink="http://www.w3.org/1999/xlink" id="tblfn3"><label>c</label><p textid="52"><italic>C</italic><sub>0</sub>, initial concentration.</p></fn>
###xml 338 339 331 332 <label xmlns:xlink="http://www.w3.org/1999/xlink">d</label>
###xml 339 340 332 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 340 343 333 336 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 353 354 346 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 354 357 347 350 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 339 358 332 351 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="53"><italic>t</italic><sub>max</sub>, time to <italic>C</italic><sub>max</sub>.</p>
###xml 338 358 331 351 <fn xmlns:xlink="http://www.w3.org/1999/xlink" id="tblfn4"><label>d</label><p textid="53"><italic>t</italic><sub>max</sub>, time to <italic>C</italic><sub>max</sub>.</p></fn>
###xml 358 359 351 352 <label xmlns:xlink="http://www.w3.org/1999/xlink">e</label>
###xml 359 360 352 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 360 365 353 354 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#189;</sub>
###xml 359 377 352 366 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="54"><italic>t</italic><sub>&#189;</sub>, half-life.</p>
###xml 358 377 351 366 <fn xmlns:xlink="http://www.w3.org/1999/xlink" id="tblfn5"><label>e</label><p textid="54"><italic>t</italic><sub>&#189;</sub>, half-life.</p></fn>
###xml 377 378 366 367 <label xmlns:xlink="http://www.w3.org/1999/xlink">f</label>
###xml 475 481 464 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per os</italic>
###xml 378 514 367 503 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="55">BA, bioavailability = (AUC p.o. &#215; dose i.v.)/(AUC i.v. &#215; dose p.o.) &#215; 100, where p.o. represents <italic>per os</italic> and i.v. represents intravenous.</p>
###xml 377 514 366 503 <fn xmlns:xlink="http://www.w3.org/1999/xlink" id="tblfn6"><label>f</label><p textid="55">BA, bioavailability = (AUC p.o. &#215; dose i.v.)/(AUC i.v. &#215; dose p.o.) &#215; 100, where p.o. represents <italic>per os</italic> and i.v. represents intravenous.</p></fn>
###xml 186 514 179 503 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><fn id="tblfn1"><label>a</label><p textid="50">AUC, area under the concentration <italic>versus</italic> time curve from 0 to the last quantifiable time point.</p></fn><fn id="tblfn2"><label>b</label><p textid="51"><italic>C</italic><sub>max</sub>, maximal concentration.</p></fn><fn id="tblfn3"><label>c</label><p textid="52"><italic>C</italic><sub>0</sub>, initial concentration.</p></fn><fn id="tblfn4"><label>d</label><p textid="53"><italic>t</italic><sub>max</sub>, time to <italic>C</italic><sub>max</sub>.</p></fn><fn id="tblfn5"><label>e</label><p textid="54"><italic>t</italic><sub>&#189;</sub>, half-life.</p></fn><fn id="tblfn6"><label>f</label><p textid="55">BA, bioavailability = (AUC p.o. &#215; dose i.v.)/(AUC i.v. &#215; dose p.o.) &#215; 100, where p.o. represents <italic>per os</italic> and i.v. represents intravenous.</p></fn></table-wrap-foot>
###xml 0 514 0 503 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="tbl1"><label>TABLE 1</label><caption><p textid="49"><bold>Pharmacokinetic parameters of AT-56</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Route</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Dose</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>AUC</bold><xref ref-type="table-fn" rid="tblfn1"><italic>a</italic></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>C</italic><sub>max</sub></bold><xref ref-type="table-fn" rid="tblfn2"><italic>b</italic></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>C</italic><sub>0</sub></bold><xref ref-type="table-fn" rid="tblfn3"><italic>c</italic></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>t</italic><sub>max</sub></bold><xref ref-type="table-fn" rid="tblfn4"><italic>d</italic></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold><italic>t</italic><sub>&#189;</sub></bold><xref ref-type="table-fn" rid="tblfn5"><italic>e</italic></xref></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>BA</bold><xref ref-type="table-fn" rid="tblfn6"><italic>f</italic></xref></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"/><td colspan="1" rowspan="1" align="right" valign="top"><italic>mg/kg</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>&#956;g&#183;h/ml</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>&#956;g/ml</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>&#956;g/ml</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>h</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>h</italic></td><td colspan="1" rowspan="1" align="center" valign="top"><italic>%</italic></td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Intravenous </td><td colspan="1" rowspan="1" align="right" valign="top"> 2 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.28 </td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 0.86 </td><td colspan="1" rowspan="1" align="center" valign="top"> 0.08 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.35 </td><td colspan="1" rowspan="1" align="center" valign="top"/></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"><italic>Per os</italic></td><td colspan="1" rowspan="1" align="right" valign="top"> 10 </td><td colspan="1" rowspan="1" align="center" valign="top"> 8.95 </td><td colspan="1" rowspan="1" align="center" valign="top"> 2.15 </td><td colspan="1" rowspan="1" align="center" valign="top"/><td colspan="1" rowspan="1" align="center" valign="top"> 0.50 </td><td colspan="1" rowspan="1" align="center" valign="top"> 1.71 </td><td colspan="1" rowspan="1" align="center" valign="top"> 82.0 </td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>a</label><p textid="50">AUC, area under the concentration <italic>versus</italic> time curve from 0 to the last quantifiable time point.</p></fn><fn id="tblfn2"><label>b</label><p textid="51"><italic>C</italic><sub>max</sub>, maximal concentration.</p></fn><fn id="tblfn3"><label>c</label><p textid="52"><italic>C</italic><sub>0</sub>, initial concentration.</p></fn><fn id="tblfn4"><label>d</label><p textid="53"><italic>t</italic><sub>max</sub>, time to <italic>C</italic><sub>max</sub>.</p></fn><fn id="tblfn5"><label>e</label><p textid="54"><italic>t</italic><sub>&#189;</sub>, half-life.</p></fn><fn id="tblfn6"><label>f</label><p textid="55">BA, bioavailability = (AUC p.o. &#215; dose i.v.)/(AUC i.v. &#215; dose p.o.) &#215; 100, where p.o. represents <italic>per os</italic> and i.v. represents intravenous.</p></fn></table-wrap-foot></table-wrap>
TABLE 1Pharmacokinetic parameters of AT-56RouteDoseAUCaCmaxbC0ctmaxdt(1/2)eBAfmg/kgmug.h/mlmug/mlmug/mlhh% Intravenous  2  1.28  0.86  0.08  2.35 Per os 10  8.95  2.15  0.50  1.71  82.0 aAUC, area under the concentration versus time curve from 0 to the last quantifiable time point.bCmax, maximal concentration.cC0, initial concentration.dtmax, time to Cmax.et(1/2), half-life.fBA, bioavailability = (AUC p.o. x dose i.v.)/(AUC i.v. x dose p.o.) x 100, where p.o. represents per os and i.v. represents intravenous.
###end p 48
###begin p 49
###xml 0 35 0 35 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Pharmacokinetic parameters of AT-56</bold>
Pharmacokinetic parameters of AT-56
###end p 49
###begin p 50
###xml 34 40 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
AUC, area under the concentration versus time curve from 0 to the last quantifiable time point.
###end p 50
###begin p 51
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1 4 1 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
Cmax, maximal concentration.
###end p 51
###begin p 52
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
C0, initial concentration.
###end p 52
###begin p 53
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1 4 1 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 14 15 14 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 15 18 15 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
tmax, time to Cmax.
###end p 53
###begin p 54
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1 6 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#189;</sub>
t(1/2), half-life.
###end p 54
###begin p 55
###xml 97 103 97 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per os</italic>
BA, bioavailability = (AUC p.o. x dose i.v.)/(AUC i.v. x dose p.o.) x 100, where p.o. represents per os and i.v. represents intravenous.
###end p 55
###begin title 56
DISCUSSION
###end title 56
###begin p 57
###xml 239 240 239 240 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 359 361 359 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">65</sup>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref49">49</xref>
###xml 638 640 638 640 <sup xmlns:xlink="http://www.w3.org/1999/xlink">54</sup>
###xml 683 685 683 685 <sup xmlns:xlink="http://www.w3.org/1999/xlink">43</sup>
In the present study, we demonstrated that AT-56 is an orally active inhibitor specific for L-PGDS with a high bioavailability. The results of the kinetic analyses indicated that AT-56 was a competitive inhibitor against the substrate, PGH2. NMR titration analysis revealed that AT-56 bound to the catalytic pocket of L-PGDS, in which the catalytic center Cys65 is located (49), being consistent with the competitive inhibition of L-PGDS by AT-56. The NMR solution structure is also in good agreement with the results of the fluorescence quenching analysis of L-PGDS, in which AT-56 interacted with the upper part of L-PGDS containing Trp54 but did not affect the fluorescence of Trp43 located in the retinoic acid-binding pocket at the bottom of the hydrophobic cavity of the enzyme.
###end p 57
###begin p 58
###xml 75 76 75 76 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 83 84 83 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 140 141 140 141 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 150 151 150 151 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 149 151 149 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>i</sub></italic>
###xml 166 167 165 166 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 169 175 168 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 214 215 213 214 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 213 215 212 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>m</sub></italic>
###xml 252 253 251 252 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 260 261 258 259 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 420 421 418 419 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 463 464 461 462 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 737 738 735 736 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 736 738 734 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>i</sub></italic>
###xml 753 754 750 751 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 756 758 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref40">40</xref>
###xml 766 767 763 764 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 765 767 762 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>i</sub></italic>
###xml 820 821 817 818 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 904 908 901 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e.</italic>
###xml 970 971 967 968 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1088 1089 1085 1086 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1179 1180 1176 1177 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1390 1392 1387 1389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1434 1435 1430 1431 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1467 1468 1463 1464 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1548 1549 1544 1545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1542 1549 1538 1545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 1344 1349 <span type="species:ncbi:9606">human</span>
Our data demonstrate that AT-56 inhibited the isomerization reaction of PGH2 to PGD2 catalyzed by L-PGDS in a competitive manner against PGH2 with a Ki value of 75 mum (Fig. 2), which was 5.3-fold higher than the Km value of the L-PGDS activity for PGH2 (14 mum) in the presence of 10% DMSO. Therefore, in the enzyme assay, AT-56 inhibited the enzyme activity clearly in a high concentration range in the presence of PGH2. On the other hand, in the absence of PGH2, AT-56 binds to the enzyme and induces the fluorescence quenching even in the low concentration range. Various inorganic selenium compounds are also known to inhibit both the purified L-PGDS and the enzyme in the crude brain supernatant in a noncompetitive manner with a Ki value of 10 mum (40). The Ki value of AT-56 was 7.5-fold higher than that of SeCl4. However, the inhibition mode of AT-56 was quite different from that of selenium; i.e. this is the first competitive inhibitor of L-PGDS against PGH2 to be reported. When the same dose of various seleno-compounds was used in cell cultures, such compounds reduced PGD2 production; however, their efficacy cannot be attributed solely to the effects on the PGD2 pathway. Seleno-compounds also inhibited the release of arachidonic acid and the production of all PGs due to the lack of specificity of action. In contrast, when human TE-671 cells were stimulated with the Ca2+ ionophore A23187 in the presence of 10 mum AT-56, only a base level of PGD2 biosynthesis was observed without changing the arachidonic acid release (Fig. 5B).
###end p 58
###begin p 59
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 4.</label>
###xml 9 52 9 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Tryptophan fluorescence quenching by AT-56.</bold>
###xml 52 53 52 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 219 220 200 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 361 362 330 331 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 433 434 401 402 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 480 483 435 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 9 498 9 453 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="60"><bold>Tryptophan fluorescence quenching by AT-56.</bold><italic>A</italic>, fluorescence quenching of intrinsic tryptophan of C89A/C186A mutant (&#9830;) and W54A/C89A/C186A mutant (&#9652;) of mouse L-PGDS by incubation with AT-56. <italic>B</italic>, fluorescence quenching of intrinsic tryptophan of the mouse L-PGDS C89A/C186A mutant in the absence (&#9830;) or presence (&#9633;) of 10 &#956;<sc>m</sc> AT-56 and that for the W54A/C89A/C186A mutant in the presence of 10 &#956;<sc>m</sc> AT-56 (&#9652;) by incubation with 13-<italic>cis</italic>-retinoic acid.</p>
###xml 9 498 9 453 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="60"><bold>Tryptophan fluorescence quenching by AT-56.</bold><italic>A</italic>, fluorescence quenching of intrinsic tryptophan of C89A/C186A mutant (&#9830;) and W54A/C89A/C186A mutant (&#9652;) of mouse L-PGDS by incubation with AT-56. <italic>B</italic>, fluorescence quenching of intrinsic tryptophan of the mouse L-PGDS C89A/C186A mutant in the absence (&#9830;) or presence (&#9633;) of 10 &#956;<sc>m</sc> AT-56 and that for the W54A/C89A/C186A mutant in the presence of 10 &#956;<sc>m</sc> AT-56 (&#9652;) by incubation with 13-<italic>cis</italic>-retinoic acid.</p></caption>
###xml 498 498 453 453 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0140969560004"/>
###xml 0 498 0 453 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig4"><label>FIGURE 4.</label><caption><p textid="60"><bold>Tryptophan fluorescence quenching by AT-56.</bold><italic>A</italic>, fluorescence quenching of intrinsic tryptophan of C89A/C186A mutant (&#9830;) and W54A/C89A/C186A mutant (&#9652;) of mouse L-PGDS by incubation with AT-56. <italic>B</italic>, fluorescence quenching of intrinsic tryptophan of the mouse L-PGDS C89A/C186A mutant in the absence (&#9830;) or presence (&#9633;) of 10 &#956;<sc>m</sc> AT-56 and that for the W54A/C89A/C186A mutant in the presence of 10 &#956;<sc>m</sc> AT-56 (&#9652;) by incubation with 13-<italic>cis</italic>-retinoic acid.</p></caption><graphic xlink:href="zbc0140969560004"/></fig>
###xml 180 185 <span type="species:ncbi:10090">mouse</span>
###xml 276 281 <span type="species:ncbi:10090">mouse</span>
FIGURE 4.Tryptophan fluorescence quenching by AT-56.A, fluorescence quenching of intrinsic tryptophan of C89A/C186A mutant (diamond) and W54A/C89A/C186A mutant (black triangle) of mouse L-PGDS by incubation with AT-56. B, fluorescence quenching of intrinsic tryptophan of the mouse L-PGDS C89A/C186A mutant in the absence (diamond) or presence (square) of 10 mum AT-56 and that for the W54A/C89A/C186A mutant in the presence of 10 mum AT-56 (black triangle) by incubation with 13-cis-retinoic acid.
###end p 59
###begin p 60
###xml 0 43 0 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Tryptophan fluorescence quenching by AT-56.</bold>
###xml 43 44 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 210 211 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 352 353 321 322 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 424 425 392 393 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 471 474 426 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 171 176 <span type="species:ncbi:10090">mouse</span>
###xml 267 272 <span type="species:ncbi:10090">mouse</span>
Tryptophan fluorescence quenching by AT-56.A, fluorescence quenching of intrinsic tryptophan of C89A/C186A mutant (diamond) and W54A/C89A/C186A mutant (black triangle) of mouse L-PGDS by incubation with AT-56. B, fluorescence quenching of intrinsic tryptophan of the mouse L-PGDS C89A/C186A mutant in the absence (diamond) or presence (square) of 10 mum AT-56 and that for the W54A/C89A/C186A mutant in the presence of 10 mum AT-56 (black triangle) by incubation with 13-cis-retinoic acid.
###end p 60
###begin p 61
###xml 33 35 33 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 75 77 75 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 83 84 83 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 82 84 82 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K<sub>i</sub></italic>
###xml 312 313 309 310 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 332 333 329 330 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 472 480 469 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
At present, the reason why the IC50 value in the cell was lower than the IC50 and Ki values for purified L-PGDS is unknown. L-PGDS requires sulfhydryl compounds, such as reduced GSH, dithiothreitol, or beta-mercaptoethanol, for its catalytic reaction, although it catalyzes the isomerization of the substrate PGH2 to the product PGD2. The endogenous sulfhydryl compounds have not been identified in its reaction, and GSH or dithiothreitol have been used as a reductant in in vitro experiments. In this present study, we used GSH for the enzyme inhibition assay of AT-56. Thus, it is possible that the reductant for the L-PGDS reaction is different from the endogenous one. It might be also possible that L-PGDS requires some other cofactor for its catalysis. AT-56 might effectively inhibit the L-PGDS reaction in the presence of such endogenous cofactor.
###end p 61
###begin p 62
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 5.</label>
###xml 9 89 9 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Inhibition of L-PGDS activity by AT-56 in TE-671 cells but not in MEG-01S cells.</bold>
###xml 224 225 223 224 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 265 266 264 265 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 276 277 275 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 296 297 295 296 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 396 397 395 396 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 483 484 480 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 497 498 494 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 591 592 588 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 650 651 646 647 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 676 677 672 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 713 715 709 711 <sup xmlns:xlink="http://www.w3.org/1999/xlink">14</sup>
###xml 720 721 716 717 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 838 840 834 836 <sup xmlns:xlink="http://www.w3.org/1999/xlink">14</sup>
###xml 883 884 878 879 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 963 964 957 958 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1130 1132 1124 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AA</italic>
###xml 9 1151 9 1145 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="63"><bold>Inhibition of L-PGDS activity by AT-56 in TE-671 cells but not in MEG-01S cells.</bold> TE-671 cells expressing L-PGDS were pretreated with various concentrations of AT-56 for 15 min and then incubated with or without 5 &#956;<sc>m</sc> A23187 for 10 min to measure prompt PGD<sub>2</sub> release. <italic>A</italic>, the amount of PGD<sub>2</sub> released from TE-671 cells was measured by enzyme immunoassay. AT-56 dose-dependently inhibits PGD<sub>2</sub> production from L-PGDS-expressing TE-671. Data are presented as the mean &#177; S.E. *, <italic>p</italic> &lt; 0.05; **, <italic>p</italic> &lt; 0.01 as compared with the value in the absence of AT-56 and in the presence of A23187. #, <italic>p</italic> &lt; 0.05 as compared with the value in the presence of 1 &#956;<sc>m</sc> AT-56 (Dunnett's test). <italic>B</italic>, selective inhibition by AT-56 of [<sup>14</sup>C]PGD<sub>2</sub> production in TE-671 cells and in H-PGDS-expressing MEG-01S cells. TE-671 and MEG-01S cells were prelabeled with [1-<sup>14</sup>C]arachidonic acid and stimulated with 5 &#956;<sc>m</sc> A23187 for 15 min in the presence of various concentrations of AT-56 (3&#8211;100 &#956;<sc>m</sc>). Radiolabeled arachidonic acid and its metabolites were extracted from the culture medium, separated by thin layer chromatography, and analyzed by autoradiography. <italic>AA</italic>, arachidonic acid.</p>
###xml 9 1151 9 1145 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="63"><bold>Inhibition of L-PGDS activity by AT-56 in TE-671 cells but not in MEG-01S cells.</bold> TE-671 cells expressing L-PGDS were pretreated with various concentrations of AT-56 for 15 min and then incubated with or without 5 &#956;<sc>m</sc> A23187 for 10 min to measure prompt PGD<sub>2</sub> release. <italic>A</italic>, the amount of PGD<sub>2</sub> released from TE-671 cells was measured by enzyme immunoassay. AT-56 dose-dependently inhibits PGD<sub>2</sub> production from L-PGDS-expressing TE-671. Data are presented as the mean &#177; S.E. *, <italic>p</italic> &lt; 0.05; **, <italic>p</italic> &lt; 0.01 as compared with the value in the absence of AT-56 and in the presence of A23187. #, <italic>p</italic> &lt; 0.05 as compared with the value in the presence of 1 &#956;<sc>m</sc> AT-56 (Dunnett's test). <italic>B</italic>, selective inhibition by AT-56 of [<sup>14</sup>C]PGD<sub>2</sub> production in TE-671 cells and in H-PGDS-expressing MEG-01S cells. TE-671 and MEG-01S cells were prelabeled with [1-<sup>14</sup>C]arachidonic acid and stimulated with 5 &#956;<sc>m</sc> A23187 for 15 min in the presence of various concentrations of AT-56 (3&#8211;100 &#956;<sc>m</sc>). Radiolabeled arachidonic acid and its metabolites were extracted from the culture medium, separated by thin layer chromatography, and analyzed by autoradiography. <italic>AA</italic>, arachidonic acid.</p></caption>
###xml 1151 1151 1145 1145 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0140969560005"/>
###xml 0 1151 0 1145 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig5"><label>FIGURE 5.</label><caption><p textid="63"><bold>Inhibition of L-PGDS activity by AT-56 in TE-671 cells but not in MEG-01S cells.</bold> TE-671 cells expressing L-PGDS were pretreated with various concentrations of AT-56 for 15 min and then incubated with or without 5 &#956;<sc>m</sc> A23187 for 10 min to measure prompt PGD<sub>2</sub> release. <italic>A</italic>, the amount of PGD<sub>2</sub> released from TE-671 cells was measured by enzyme immunoassay. AT-56 dose-dependently inhibits PGD<sub>2</sub> production from L-PGDS-expressing TE-671. Data are presented as the mean &#177; S.E. *, <italic>p</italic> &lt; 0.05; **, <italic>p</italic> &lt; 0.01 as compared with the value in the absence of AT-56 and in the presence of A23187. #, <italic>p</italic> &lt; 0.05 as compared with the value in the presence of 1 &#956;<sc>m</sc> AT-56 (Dunnett's test). <italic>B</italic>, selective inhibition by AT-56 of [<sup>14</sup>C]PGD<sub>2</sub> production in TE-671 cells and in H-PGDS-expressing MEG-01S cells. TE-671 and MEG-01S cells were prelabeled with [1-<sup>14</sup>C]arachidonic acid and stimulated with 5 &#956;<sc>m</sc> A23187 for 15 min in the presence of various concentrations of AT-56 (3&#8211;100 &#956;<sc>m</sc>). Radiolabeled arachidonic acid and its metabolites were extracted from the culture medium, separated by thin layer chromatography, and analyzed by autoradiography. <italic>AA</italic>, arachidonic acid.</p></caption><graphic xlink:href="zbc0140969560005"/></fig>
FIGURE 5.Inhibition of L-PGDS activity by AT-56 in TE-671 cells but not in MEG-01S cells. TE-671 cells expressing L-PGDS were pretreated with various concentrations of AT-56 for 15 min and then incubated with or without 5 mum A23187 for 10 min to measure prompt PGD2 release. A, the amount of PGD2 released from TE-671 cells was measured by enzyme immunoassay. AT-56 dose-dependently inhibits PGD2 production from L-PGDS-expressing TE-671. Data are presented as the mean +/- S.E. *, p < 0.05; **, p < 0.01 as compared with the value in the absence of AT-56 and in the presence of A23187. #, p < 0.05 as compared with the value in the presence of 1 mum AT-56 (Dunnett's test). B, selective inhibition by AT-56 of [14C]PGD2 production in TE-671 cells and in H-PGDS-expressing MEG-01S cells. TE-671 and MEG-01S cells were prelabeled with [1-14C]arachidonic acid and stimulated with 5 mum A23187 for 15 min in the presence of various concentrations of AT-56 (3-100 mum). Radiolabeled arachidonic acid and its metabolites were extracted from the culture medium, separated by thin layer chromatography, and analyzed by autoradiography. AA, arachidonic acid.
###end p 62
###begin p 63
###xml 0 80 0 80 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Inhibition of L-PGDS activity by AT-56 in TE-671 cells but not in MEG-01S cells.</bold>
###xml 215 216 214 215 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 256 257 255 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 267 268 266 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 287 288 286 287 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 387 388 386 387 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 474 475 471 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 488 489 485 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 582 583 579 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 641 642 637 638 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 667 668 663 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 704 706 700 702 <sup xmlns:xlink="http://www.w3.org/1999/xlink">14</sup>
###xml 711 712 707 708 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 829 831 825 827 <sup xmlns:xlink="http://www.w3.org/1999/xlink">14</sup>
###xml 874 875 869 870 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 954 955 948 949 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1121 1123 1115 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AA</italic>
Inhibition of L-PGDS activity by AT-56 in TE-671 cells but not in MEG-01S cells. TE-671 cells expressing L-PGDS were pretreated with various concentrations of AT-56 for 15 min and then incubated with or without 5 mum A23187 for 10 min to measure prompt PGD2 release. A, the amount of PGD2 released from TE-671 cells was measured by enzyme immunoassay. AT-56 dose-dependently inhibits PGD2 production from L-PGDS-expressing TE-671. Data are presented as the mean +/- S.E. *, p < 0.05; **, p < 0.01 as compared with the value in the absence of AT-56 and in the presence of A23187. #, p < 0.05 as compared with the value in the presence of 1 mum AT-56 (Dunnett's test). B, selective inhibition by AT-56 of [14C]PGD2 production in TE-671 cells and in H-PGDS-expressing MEG-01S cells. TE-671 and MEG-01S cells were prelabeled with [1-14C]arachidonic acid and stimulated with 5 mum A23187 for 15 min in the presence of various concentrations of AT-56 (3-100 mum). Radiolabeled arachidonic acid and its metabolites were extracted from the culture medium, separated by thin layer chromatography, and analyzed by autoradiography. AA, arachidonic acid.
###end p 63
###begin p 64
###xml 50 51 50 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref43">43</xref>
###xml 365 366 365 366 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Recently, we demonstrated that L-PGDS produced PGD2 coupled with COX-2 in TE-671 cells (43). L-PGDS coupled to COX-2 may be more sensitive to AT-56 than L-PGDS itself. Since AT-56 is a relatively lipophilic compound, its local concentration around the L-PGDS-COX-2 complex within endoplasmic reticulum may be high enough to efficiently inhibit the production of PGD2 within the cell.
###end p 64
###begin p 65
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref38">38</xref>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref39">39</xref>
###xml 381 389 381 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 394 401 394 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
Although both L-PGDS and H-PGDS became evolutionarily diversified from quite different ancestor gene families (38, 39), these enzymes can catalyze the same isomerization reaction. HQL-79 recently has been identified as an H-PGDS inhibitor. In this study, we found that AT-56, which is an HQL-79-derivative compound, also has an inhibitory activity against the L-PGDS reaction both in vitro and in vivo, suggesting that the active site architecture for the substrate binding and the catalytic reaction mechanism of L-PGDS could be similar to those of H-PGDS.
###end p 65
###begin p 66
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 6.</label>
###xml 42 43 42 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 9 174 9 174 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Inhibitory effect of AT-56 on PGD<sub>2</sub> production by stab wounding in H-PGDS KO mice and therapeutic effect on antigen-induced lung inflammation in human L-PGDS TG mice.</bold>
###xml 174 175 174 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 290 291 290 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 520 521 518 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 534 535 532 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 604 622 602 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p.o., per os. BALF</italic>
###xml 9 653 9 651 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="67"><bold>Inhibitory effect of AT-56 on PGD<sub>2</sub> production by stab wounding in H-PGDS KO mice and therapeutic effect on antigen-induced lung inflammation in human L-PGDS TG mice.</bold><italic>A</italic>, AT-56 was orally administered 1 h before the stab wounding, and brains were collected 10 min after the wounding. <italic>B</italic>, AT-56 was orally administered 1 h before and 24 h after the antigen exposure. The accumulated cells in the bronchoalveolar lavage fluid were collected 48 h after the antigen exposure. Data are presented as the mean &#177; S.E. *, <italic>p</italic> &lt; 0.05; **, <italic>p</italic> &lt; 0.01 as compared with the vehicle-treated group (Dunnett's test). <italic>p.o., per os. BALF</italic>, bronchoalveolar lavage fluid.</p>
###xml 9 653 9 651 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="67"><bold>Inhibitory effect of AT-56 on PGD<sub>2</sub> production by stab wounding in H-PGDS KO mice and therapeutic effect on antigen-induced lung inflammation in human L-PGDS TG mice.</bold><italic>A</italic>, AT-56 was orally administered 1 h before the stab wounding, and brains were collected 10 min after the wounding. <italic>B</italic>, AT-56 was orally administered 1 h before and 24 h after the antigen exposure. The accumulated cells in the bronchoalveolar lavage fluid were collected 48 h after the antigen exposure. Data are presented as the mean &#177; S.E. *, <italic>p</italic> &lt; 0.05; **, <italic>p</italic> &lt; 0.01 as compared with the vehicle-treated group (Dunnett's test). <italic>p.o., per os. BALF</italic>, bronchoalveolar lavage fluid.</p></caption>
###xml 653 653 651 651 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0140969560006"/>
###xml 0 653 0 651 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig6"><label>FIGURE 6.</label><caption><p textid="67"><bold>Inhibitory effect of AT-56 on PGD<sub>2</sub> production by stab wounding in H-PGDS KO mice and therapeutic effect on antigen-induced lung inflammation in human L-PGDS TG mice.</bold><italic>A</italic>, AT-56 was orally administered 1 h before the stab wounding, and brains were collected 10 min after the wounding. <italic>B</italic>, AT-56 was orally administered 1 h before and 24 h after the antigen exposure. The accumulated cells in the bronchoalveolar lavage fluid were collected 48 h after the antigen exposure. Data are presented as the mean &#177; S.E. *, <italic>p</italic> &lt; 0.05; **, <italic>p</italic> &lt; 0.01 as compared with the vehicle-treated group (Dunnett's test). <italic>p.o., per os. BALF</italic>, bronchoalveolar lavage fluid.</p></caption><graphic xlink:href="zbc0140969560006"/></fig>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 153 158 <span type="species:ncbi:9606">human</span>
###xml 169 173 <span type="species:ncbi:10090">mice</span>
FIGURE 6.Inhibitory effect of AT-56 on PGD2 production by stab wounding in H-PGDS KO mice and therapeutic effect on antigen-induced lung inflammation in human L-PGDS TG mice.A, AT-56 was orally administered 1 h before the stab wounding, and brains were collected 10 min after the wounding. B, AT-56 was orally administered 1 h before and 24 h after the antigen exposure. The accumulated cells in the bronchoalveolar lavage fluid were collected 48 h after the antigen exposure. Data are presented as the mean +/- S.E. *, p < 0.05; **, p < 0.01 as compared with the vehicle-treated group (Dunnett's test). p.o., per os. BALF, bronchoalveolar lavage fluid.
###end p 66
###begin p 67
###xml 33 34 33 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 0 165 0 165 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Inhibitory effect of AT-56 on PGD<sub>2</sub> production by stab wounding in H-PGDS KO mice and therapeutic effect on antigen-induced lung inflammation in human L-PGDS TG mice.</bold>
###xml 165 166 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 281 282 281 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 511 512 509 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 525 526 523 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 595 613 593 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p.o., per os. BALF</italic>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
###xml 144 149 <span type="species:ncbi:9606">human</span>
###xml 160 164 <span type="species:ncbi:10090">mice</span>
Inhibitory effect of AT-56 on PGD2 production by stab wounding in H-PGDS KO mice and therapeutic effect on antigen-induced lung inflammation in human L-PGDS TG mice.A, AT-56 was orally administered 1 h before the stab wounding, and brains were collected 10 min after the wounding. B, AT-56 was orally administered 1 h before and 24 h after the antigen exposure. The accumulated cells in the bronchoalveolar lavage fluid were collected 48 h after the antigen exposure. Data are presented as the mean +/- S.E. *, p < 0.05; **, p < 0.01 as compared with the vehicle-treated group (Dunnett's test). p.o., per os. BALF, bronchoalveolar lavage fluid.
###end p 67
###begin p 68
###xml 210 211 210 211 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 340 341 340 341 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 427 428 427 428 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 479 480 479 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 492 493 492 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref7">7</xref>
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
###xml 609 611 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref36">36</xref>
###xml 731 732 731 732 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Here, we demonstrated pharmacologically and biochemically that AT-56 is an orally effective inhibitor selective for L-PGDS. Especially, it should be noted that AT-56 specifically inhibited the production of PGD2 catalyzed by L-PGDS but only marginally affected the production of other prostanoids. In this sense, AT-56 is an even better PGD2-blocking compound than inorganic selenium compounds. Earlier we demonstrated that PGD2 produced by L-PGDS regulates physiological sleep (1) and pain (7) and also that L-PGDS acts as an extracellular transporter for various useful or harmful hydrophobic compounds (34-36). Thus, AT-56 may be predicted to selectively suppress the drowsiness or pain reaction mediated by L-PGDS-catalyzed PGD2 without showing the various side effects caused by the suppression of cytoprotective and anti-inflammatory PGs.
###end p 68
###begin p 69
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 7.</label>
###xml 79 80 79 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 108 109 108 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 9 151 9 151 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Time courses of plasma concentrations of AT-56 after oral (10 mg/kg) (<italic>A</italic>) or intravenous (2 mg/kg) (<italic>B</italic>) administration of AT-56 to C57BL/6 mice.</bold>
###xml 193 194 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 9 210 9 208 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="70"><bold>Time courses of plasma concentrations of AT-56 after oral (10 mg/kg) (<italic>A</italic>) or intravenous (2 mg/kg) (<italic>B</italic>) administration of AT-56 to C57BL/6 mice.</bold> Data are presented as the mean &#177; S.E., <italic>n</italic> = 3/time point.</p>
###xml 9 210 9 208 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="70"><bold>Time courses of plasma concentrations of AT-56 after oral (10 mg/kg) (<italic>A</italic>) or intravenous (2 mg/kg) (<italic>B</italic>) administration of AT-56 to C57BL/6 mice.</bold> Data are presented as the mean &#177; S.E., <italic>n</italic> = 3/time point.</p></caption>
###xml 210 210 208 208 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0140969560007"/>
###xml 0 210 0 208 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig7"><label>FIGURE 7.</label><caption><p textid="70"><bold>Time courses of plasma concentrations of AT-56 after oral (10 mg/kg) (<italic>A</italic>) or intravenous (2 mg/kg) (<italic>B</italic>) administration of AT-56 to C57BL/6 mice.</bold> Data are presented as the mean &#177; S.E., <italic>n</italic> = 3/time point.</p></caption><graphic xlink:href="zbc0140969560007"/></fig>
###xml 146 150 <span type="species:ncbi:10090">mice</span>
FIGURE 7.Time courses of plasma concentrations of AT-56 after oral (10 mg/kg) (A) or intravenous (2 mg/kg) (B) administration of AT-56 to C57BL/6 mice. Data are presented as the mean +/- S.E., n = 3/time point.
###end p 69
###begin p 70
###xml 70 71 70 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 99 100 99 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 0 142 0 142 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Time courses of plasma concentrations of AT-56 after oral (10 mg/kg) (<italic>A</italic>) or intravenous (2 mg/kg) (<italic>B</italic>) administration of AT-56 to C57BL/6 mice.</bold>
###xml 184 185 182 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
Time courses of plasma concentrations of AT-56 after oral (10 mg/kg) (A) or intravenous (2 mg/kg) (B) administration of AT-56 to C57BL/6 mice. Data are presented as the mean +/- S.E., n = 3/time point.
###end p 70
###begin p 71
###xml 186 194 186 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 199 206 199 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 542 543 542 543 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
We did not detect any acute toxic effects of AT-56 after its oral administration even at a dose of 100 mg/kg. AT-56 possesses a direct and previously unknown inhibitory effect on L-PGDS in vitro and in vivo, suggesting that AT-56 might be a useful prototypic molecule to develop selective and/or nonselective inhibitors for L-PGDS and H-PGDS, which may act as anti-somnolence and anti-inflammatory drugs, respectively. The development of such selective and nonselective inhibitors of both enzymes would be helpful to determine the role of PGD2 in animal models. Such inhibitors would be drug candidates or actual drugs.
###end p 71
###begin p 72
###xml 432 437 <span type="species:ncbi:9606">human</span>
We thank O. Hayaishi (Osaka Bioscience Institute) for generous support of this study. We also thank Dr. K. Shigeno and Dr. K. Tanaka (TAIHO Pharmaceutical Company) for chemical synthesis and pharmacokinetics analysis of AT-56, respectively; T. Tsurumura and M. Sakata (Osaka Bioscience Institute) for assistance in enzyme assays and in vivo experiments, respectively; and Dr. M. Mase (Nagoya City University Hospital) for providing human CSF.
###end p 72
###begin p 73
###xml 49 50 49 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 55 56 55 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 61 67 61 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2&#945;</sub>
###xml 76 77 72 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 94 95 90 91 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 97 98 93 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 100 106 96 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2&#945;</sub>
###xml 113 114 105 106 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 166 169 158 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a,d</italic>
###xml 199 200 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 472 473 464 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
The abbreviations and trivial names used are: PGD2, PGE2, PGF2alpha, and PGH2, prostaglandin D2,E2,F2alpha, and H2, respectively; PG, prostaglandin; AT-56, 4-dibenzo[a,d]cyclohepten-5-ylidene-1-[4-(2H-tetrazol-5-yl)-butyl]-piperidine; PGDS, prostaglandin D synthase; L-PGDS, lipocalin-type prostaglandin D synthase; H-PGDS, hematopoietic prostaglandin D synthase; CSF, cerebrospinal fluid; COX, cyclooxygenase; KO, knockout; TG, transgenic; HQL-79, 4-benzhydryloxy-1-(3-(1H-tetrazol-5-yl)-propyl)-piperidine.
###end p 73

